Agenus to Report Third Quarter Earnings
Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agenus Inc. (NASDAQ: AGEN) will announce its Q3 2020 financial results before the market opens on October 29, 2020. A conference call and webcast will follow at 8:30 AM ET for a discussion of the results and corporate update. Agenus specializes in immuno-oncology with an extensive pipeline including checkpoint antibodies, cell therapies, and vaccines aimed at enhancing immune responses to cancer and infections. The call will be accessible via the company’s website.
Positive
- Leading immuno-oncology company with an extensive pipeline of checkpoint antibodies and therapies.
- Plans to release Q3 2020 financial results and provide corporate updates, which may offer insight into growth and strategic direction.
Negative
- None.
Details
News Market Reaction – AGEN
The recorded move for AGEN in the trading session of this news was -1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast on Thursday, October 29, 2020 from 8:30 – 9:30 am
LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will release its third quarter 2020 financial results before the market opens on Thursday, October 29, 2020. Agenus executives will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the results and to provide a corporate update.
Live Call: Dial (833) 614-1394 (US) or (914) 987-7115 (International)
Webcast: The call will be accessible from the Company website’s Events & Presentations page at https://investor.agenusbio.com/events-and-presentations or via https://edge.media-server.com/mmc/p/mbkjgw8w. A replay will be available after the call.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact
Agenus Inc.
Caroline Bafundo
212-994-8209
Caroline.bafundo@agenusbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.